Shudong Wang
University of South Australia(AU)Chinese Academy of Sciences(CN)Nanjing University of Information Science and Technology(CN)PYC Therapeutics (Australia)(AU)Qingdao Academy of Intelligent Industries(CN)Institute of Remote Sensing and Digital Earth(CN)Institute of Software(CN)Aerospace Information Research Institute(CN)State Key Laboratory of Chemical Engineering(CN)Shenzhen Academy of Aerospace Technology(CN)China University of Petroleum, East China(CN)The University of Adelaide(AU)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Protein Degradation and Inhibitors, Cancer Mechanisms and Therapy, Microtubule and mitosis dynamics
Most-Cited Works
- → In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)(2002)363 cited
- → Targeting CDK2 in cancer: challenges and opportunities for therapy(2019)317 cited
- → Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update(2018)278 cited
- → Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer(2018)164 cited
- → Targeting CDK6 in cancer: State of the art and new insights(2015)163 cited
- → 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity(2004)152 cited